Central Lab Market Dynamics and Outsourcing Performance
[ISR’s “Central Lab Market Dynamics and Outsourcing Performance” report surveyed 101 respondents with decision-making authority for central lab services.]
Expected growth of central lab service areas
Respondents indicated that the central lab services projected to see the most growth over the next three years are biomarkers and genomics . Specifically, “biomarkers from Phase IIb through commercialization” is expected to experience the largest rate of growth.
Regional distribution
Based on feedback from industry experts, ISR’s report asked several different types of questions surrounding the historic, current and future geographical mix of central lab activities.
From a macro point of view, the distribution of central lab testing shows a substantial drop in testing in North America and modest gains in emerging pharma regions. With that being said, respondents indicate that the majority of central lab tests (72%) will continue to be run in North America and Western Europe through 2015.
To dive a little deeper, ISR asked respondents to indicate which countries they had been using more of today as compared to two years ago and which countries they had been using less of two years ago compared to today. Results show that China has seen the largest increase in net usage (from 4% to 20%), while North America has experienced a slight decrease in net usage (28% to 27%). One important finding from these two
questions is that respondents are indicating they are performing central lab tests in more countries as the vast majority of countries are showing a net increase in usage.
Attributes sponsors use to select central lab providers
With over half of the respondents surveyed indicating that ALL of their central lab activities are outsourced, attributes sponsors use to select service providers are more important than ever.
In selecting a central lab service provider, respondents indicated that “Quality” (34%) is the single, most important attribute. When respondents were asked to select their top 5 most important attributes for selection, “Quality” (65%) was followed closely by “Sample turnaround time” (56%).
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
